Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 3/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.53 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902963 | 1.00 | BPTF (0.64) | BPTFADRB1PLD1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL20339255 | 0.98 | BPTF (0.62) | BPTFADRB1PLD1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL29903032 | 0.98 | BPTF (0.62) | BPTFADRB1PLD1GRIN2DGRIN3B | |
| SCHEMBL5235313 | 0.93 | BPTF (0.58) | BPTFADRB1PLD1GRIN2DGRIN3B | |
| SCHEMBL21424864 | 0.86 | GRIN2D (0.59) | BPTFGRIN2DGRIN3BGRIN1GRIN2A | |
| Tert-Butyl Formate SCHEMBL27875872 | 0.84 | BPTF (0.50) | BPTFADRB1PLD1GRIN2DGRIN3B | |
| SCHEMBL806544 | 0.82 | CNR2 (0.59) | BPTFGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11988476 | 0.82 | GRIN2D (0.56) | BPTFGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL31415358 | 0.82 | CNR2 (0.59) | BPTFGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL82447 | 0.81 | CNR2 (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-12-26 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024054591-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-3705480-B1 | CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University-Of The Commonwealth System Higher Education (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2006072435-A1 | SULFANYL SUBSTITUTED PHENYL METHANONES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005108368-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245745-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | BPTF 2839/4885ADRB1 79/4885PLD1 1286/4885 |
| US-20060149062-A1 | Sulfanyl substituted phenyl methanones | SULT1A1, SULT2A1, SULT1E1 | BPTF 2943/4885ADRB1 340/4885PLD1 3238/4885 |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | BPTF 583/4885ADRB1 2811/4885PLD1 2173/4885 |
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | BPTF 2548/4885ADRB1 3457/4885PLD1 4145/4885 |
| US-20050245745-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | BPTF 3207/4885ADRB1 646/4885PLD1 902/4885 |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | BPTF 455/4885ADRB1 97/4885PLD1 1138/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | BPTF 3207/4885ADRB1 646/4885PLD1 902/4885 |
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | BPTF 3207/4885ADRB1 646/4885PLD1 902/4885 |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | BPTF 2839/4885ADRB1 79/4885PLD1 1286/4885 |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | BPTF 3226/4885ADRB1 95/4885PLD1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.